{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:16:37Z","timestamp":1756995397387,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10840-020-00865-0","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T01:02:59Z","timestamp":1601427779000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ranolazine depresses conduction of rapid atrial depolarizations in a beating rabbit heart model"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0350-803X","authenticated-orcid":false,"given":"I.","family":"Aidonidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Simopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Stravela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Dipla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Stamatiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hatziefthimiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P-A.","family":"Molyvdas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"865_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.amjcard.2012.04.044","volume":"110","author":"N Fragakis","year":"2012","unstructured":"Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012;110:673\u20137.","journal-title":"Am J Cardiol"},{"key":"865_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/europace\/eut407","volume":"16","author":"KC Koskinas","year":"2014","unstructured":"Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace. 2014;16:973\u20139.","journal-title":"Europace."},{"key":"865_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/pace.13048","volume":"40","author":"N Tsanaxidis","year":"2017","unstructured":"Tsanaxidis N, Aidonidis I, Hatziefthimiou A, Daskalopoulou SS, Giamouzis G, Triposkiadis F, et al. Ranolazine added to amiodarone facilitates earlier conversion of atrial fibrillation compared to amiodarone-only therapy. Pacing Clin Electrophysiol. 2017;40:372\u20138.","journal-title":"Pacing Clin Electrophysiol"},{"key":"865_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1074248412453874","volume":"18","author":"I Aidonidis","year":"2013","unstructured":"Aidonidis I, Doulas K, Hatziefthimiou A, Tagarakis G, Simopoulos V, Rizos I, et al. Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther. 2013;18:94\u2013101.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"865_CR5","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.hrthm.2014.05.038","volume":"11","author":"AA Bhimani","year":"2014","unstructured":"Bhimani AA, Yasuda T, Sadrpour SA, Khrestian CM, Lee S, Zeng D, et al. Ranolazine terminates atrial flutter and fibrillation in a canine model. Heart Rhythm. 2014;11:1592\u20139.","journal-title":"Heart Rhythm"},{"key":"865_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jelectrocard.2009.07.007","volume":"42","author":"C Antzelevitch","year":"2009","unstructured":"Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J Electrocardiol. 2009;42:543\u20138.","journal-title":"J Electrocardiol"},{"key":"865_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jacc.2010.07.046","volume":"57","author":"AJ Camm","year":"2011","unstructured":"Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"865_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/cvr\/cvt007","volume":"98","author":"T Suzuki","year":"2013","unstructured":"Suzuki T, Morishima M, Kato S, Ueda N, Honjo H, Kamiya K. Atrial selectivity in Na + channel blockade by acute amiodarone. Cardiovasc Res. 2013;98:136\u201344.","journal-title":"Cardiovasc Res"},{"key":"865_CR9","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/oxfordjournals.eurheartj.a060848","volume":"16","author":"BS Koller","year":"1995","unstructured":"Koller BS, Karasik PE, Solomon AJ, Franz MR. Prolongation of conduction time during premature stimulation in the human atrium is primarily caused by local stimulus response latency. Eur Heart J. 1995;16:1920\u20134.","journal-title":"Eur Heart J"},{"key":"865_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1053\/eupc.2001.0183","volume":"3","author":"Z Li","year":"2001","unstructured":"Li Z, Hertervig E, Yuan S, Yang Y, Lin Z, Olsson SB. Dispersion of atrial repolarization in patients with paroxysmal atrial fibrillation. Europace. 2001;3:285\u201391.","journal-title":"Europace."},{"key":"865_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0003319713477911","volume":"65","author":"V Simopoulos","year":"2014","unstructured":"Simopoulos V, Tagarakis GI, Daskalopoulou SS, Daskalopoulos ME, Lenos A, Chryssagis K, et al. Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. Angiology. 2014;65:294\u20137.","journal-title":"Angiology."},{"key":"865_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10557-018-6832-8","volume":"32","author":"V Simopoulos","year":"2018","unstructured":"Simopoulos V, Hevas A, Hatziefthimiou A, Dipla K, Skoularigis I, Tsilimingas N, et al. Amiodarone plus ranolazine for conversion of post-cardiac surgery atrial fibrillation: enhanced effectiveness in reduced versus preserved ejection fraction patients. Cardiovasc Drugs Ther. 2018;32:559\u201365.","journal-title":"Cardiovasc Drugs Ther"},{"key":"865_CR13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/eurjhf\/hfs163","volume":"14","author":"G Frommeyer","year":"2012","unstructured":"Frommeyer G, Schmidt M, Clau\u00df C, Kaese S, Stypmann J, Pott C, et al. Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. Eur J Heart Fail. 2012;14:1322\u201331.","journal-title":"Eur J Heart Fail"},{"key":"865_CR14","first-page":"1096","volume":"19","author":"EW Black-Maier","year":"2017","unstructured":"Black-Maier EW, Pokorney SD, Barnett AS, Liu P, Shrader P, Ng J, et al. Ranolazine reduces atrial fibrillatory wave frequency. Europace. 2017;19:1096\u2013100.","journal-title":"Europace."},{"issue":"10","key":"865_CR15","volume":"12","author":"RJ Ramirez","year":"2019","unstructured":"Ramirez RJ, Takemoto Y, Martins RP, Filgueiras-Rama D, Ennis SR, Mironov S, et al. Mechanisms by which ranolazine terminates paroxysmal but not persistent atrial fibrillation. Circ Arrhythm Electrophysiol. 2019;12(10):e005557.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"865_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/europace\/eus399","volume":"15","author":"P Milberg","year":"2013","unstructured":"Milberg P, Frommeyer G, Ghezelbash S, Rajamani S, Osada N, Razvan R, et al. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. Europace. 2013;15:761\u20139.","journal-title":"Europace."},{"key":"865_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1124\/jpet.102.046755","volume":"305","author":"P Kirchhof","year":"2003","unstructured":"Kirchhof P, Degen H, Franz MR, Eckardt L, Fabritz L, Milberg P, et al. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. J Pharmacol Exp Ther. 2003;305:257\u201363.","journal-title":"J Pharmacol Exp Ther"},{"key":"865_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0008-6363(98)00268-5","volume":"41","author":"MR Franz","year":"1999","unstructured":"Franz MR. Current status of monophasic action potential recording: theories, measurements and interpretations. Cardiovasc Res. 1999;41:25\u201340.","journal-title":"Cardiovasc Res"},{"key":"865_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/jpet.111.186395","volume":"340","author":"A Burashnikov","year":"2012","unstructured":"Burashnikov A, Belardinelli L, Antzelevitch C. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. J Pharmacol Exp Ther. 2012;340:161\u20138.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-020-00865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-020-00865-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-020-00865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T05:24:16Z","timestamp":1633065856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-020-00865-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1007\/s10840-020-00865-0","relation":{},"ISSN":["1383-875X","1572-8595"],"issn-type":[{"type":"print","value":"1383-875X"},{"type":"electronic","value":"1572-8595"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"9 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental protocol procedures were approved by the Institutional Animal Care Committee. The study was conducted in accordance with the guidelines of the European Council on Animal Care.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}